Entasis Therapeutics names Ipsen CEO David Meek as chairman

25 June 2019

USA-based antibacterial products developer Entasis Therapeutics (Nasdaq: ETTX) has announced the appointment of David Meek, currently chief executive of French pharma company Ipsen (Euronext: IPN,) as chairman of the board of directors, effective immediately.

Mr Meek will succeed Nicholas Galakatos, who will continue to serve as a director on the board of Entasis, which was spun out by Anglo-Swedish pharma major AstraZeneca (LSE: AZN) in 2015.

American born Mr Meek has over 25 years of experience in the healthcare industry where he has held various global executive positions at major pharmaceutical and biotechnology companies. Currently the CEO and board member of Ipsen, he also serves on the board of directors of uniQure, PhRMA, and the EFPIA. Prior to joining Ipsen in 2016, Mr Meek was executive vice president and president of the oncology division of Baxalta. Previously, he held executive positions at Endocyte and Novartis. Mr Meek began his career at Johnson & Johnson and Janssen Pharmaceuticals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK